FDA Reminds Doctors: Please Don't Transplant Sepsis Into People
Published Date: 1/7/2025
Notice
Summary
The FDA just released new rules to help stop infections like sepsis from spreading through donated human cells and tissues. This affects all places that check donors before using their cells or tissues in treatments. These updated recommendations start right away and aim to keep patients safer without adding big costs or delays.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Immediate sepsis screening guidance
The FDA released a final guidance titled "Recommendations To Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)" that is available for immediate implementation as of January 7, 2025. If you make donor eligibility determinations for human cells or tissues, the guidance provides recommendations to reduce the risk of transmitting infections that cause sepsis.
Separate tuberculosis screening guidance
In the same Federal Register issue, FDA announced availability of a separate final guidance titled "Recommendations To Reduce the Risk of Transmission of Mycobacterium Tuberculosis (Mtb) by HCT/Ps" that is also for immediate implementation as of January 7, 2025. If you make donor eligibility determinations, that guidance provides recommendations for screening donors for evidence of, and risk factors for, Mtb, which can cause sepsis.
Supersedes 2007 sepsis guidance
The new guidance supersedes the sepsis-related information in the August 2007 guidance on donor eligibility for HCT/Ps. If your establishment used the August 2007 recommendations, you should review and consider the updated recommendations announced January 7, 2025.
No new paperwork burden
The guidance itself contains no new collection of information and refers to previously approved collections under OMB control number 0910-0543 for 21 CFR 1271 activities such as donor screening, testing, and recordkeeping. If you operate an HCT/P establishment, the guidance does not add new paperwork requirements beyond those already covered under OMB 0910-0543.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20724, Notice of Intent To Prepare a Supplemental Environmental Impact Statement for the Sentinel Deployment and Minuteman III Decommissioning and Disposal
The Air Force is updating its plan to replace old Minuteman III missiles with new Sentinel missiles across five states, including Wyoming, Montana, and North Dakota. They’re checking how these changes might affect the environment and want your thoughts during a 30-day comment period starting now. This update could impact local lands and communities, with careful reviews to keep things safe and smart.
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20708, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Amend the IEX Equities Fee Schedule
IEX is shaking up its fee schedule starting November 1, 2026, by tweaking who gets rebates for adding displayed liquidity and changing rebate amounts. This affects IEX members who trade stocks, giving them new ways to save or earn more on fees. The changes kick in right away after filing, so traders should get ready to adjust their strategies and cash flow.
2026-20710, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Modify the Required Criteria To Qualify for the Reduced Incremental Fee
Investors Exchange (IEX) is changing the rules for who can get a discount on certain trading fees. Starting November 1, 2026, members will need to meet new criteria to qualify for the reduced incremental fee, which could save or cost them money depending on their trading activity. This change affects all IEX members and kicks in right away to keep things fair and clear.
2026-20779, Passenger Vehicle and Light Truck Tires From Thailand: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce found that tires from Thailand were sold in the U.S. for less than their normal price between July 2024 and June 2025. This means some importers might have to pay extra duties to keep things fair. The review process had some delays due to government shutdowns, but now the preliminary results are out and open for comments.
2026-20763, National Environmental Policy Act Implementing Procedures: Wintertime Oil and Gas Exploration in the National Petroleum Reserve in Alaska Categorical Exclusion
Starting October 9, 2026, the Department of the Interior is making it easier and faster to approve wintertime oil and gas exploration in Alaska’s National Petroleum Reserve by adding a special rule that skips some usual paperwork. This change mainly affects energy companies working in the area and aims to speed up projects while still protecting the environment. No new costs are expected, but the process will be smoother and quicker.
Previous / Next Documents
Previous: 2024-31537, Study of Sex Differences in the Clinical Evaluation of Medical Products; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to make sure medical studies include enough women and men to spot any differences in how treatments work. This means drug makers and researchers will need to design smarter studies and share sex-specific results when they apply for approval. Comments on this draft are open until April 7, 2025, so get ready to weigh in and help shape the future of fairer medical testing!
Next: 2024-31539, Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers; Guidance for Industry; Availability; Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request
The FDA just released final guidance on how companies can share scientific info about unapproved uses of approved medical products with health care providers. This update affects medical product firms and aims to clarify communication rules, but it won’t take effect until the Office of Management and Budget reviews the info collection by February 21, 2025. No new costs yet, but companies should get ready to follow these clearer, friendlier rules soon!